Vertex Pharmaceuticals Incorporated
HealthcareNASDAQ:VRTX · NASDAQ Global Select
-$1.21 today
Vol 0.43M · Avg 1.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.2%
avg 11.6%
ROIC
18.1%
avg 7.6%
ROA
15.1%
avg 10.6%
Analysis
ROE is currently the strongest return metric at 21.2% versus its period average of 11.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Reshma Kewalramani FASN | Chief Executive Officer, President & Director | $6.14M | — | 53 | $100,003.00 | 0.04% |
Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer | $2.99M | — | 58 | $47,042.00 | 0.02% |
Mark Bunnage D.Phil | Executive Vice President & Chief Scientific Officer | $2.39M | — | 57 | $7,284.00 | <0.01% |
Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | $2.27M | — | 63 | $21,015.00 | <0.01% |
Ourania Tatsis | Executive Vice President and Chief Regulatory & Quality Officer | $2.07M | — | 56 | $46,763.00 | 0.02% |
Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer | $1.88M | — | 58 | $55,570.00 | 0.02% |
Jeffrey Marc Leiden | Executive Chairman | — | — | 70 | $34,797.00 | 0.01% |
Kristen C. Ambrose | Senior Vice President & Chief Accounting Officer | — | — | 49 | $6,624.00 | <0.01% |
Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | — | — | 48 | $20,729.00 | <0.01% |
Susie Lisa | Senior Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
83
$144.46M
Net Sentiment
$144.46M
Net selling
Most Active
LEIDEN JEFFREY M
14 transactions
1–10 of 83
Analysis
Insiders reported 0 buys worth $0.00 and 83 sells worth $144.46M over the last 12 months. That adds up to net selling of $144.46M. LEIDEN JEFFREY M was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | -12.2% | +21.6% (15yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Recent growth has been strongest in Revenue at -12.2% over three years. Forward estimates point to Revenue at +21.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CVS Health Corporation
NYSE:CVS
$129.95B
Stryker Corporation
NYSE:SYK
$120.13B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
GSK plc
NYSE:GSK
$106.55B
Sanofi
NASDAQ:SNY
$106.46B
Medtronic plc
NYSE:MDT
$103.10B
McKesson Corporation
NYSE:MCK
$94.83B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.32B
argenx SE
NASDAQ:ARGX
$55.65B
Who manages VRTX?
Vertex Pharmaceuticals Incorporated (VRTX) lists 10 active executives. The top listed executive is Amit K. Sachdev, Executive Vice President & Chief Patient and External Affairs Officer.
Are VRTX insiders buying or selling?
Recent insider activity shows net selling of $187.78M.
Explore More
Continue the stock analysis
Jump to another research area for this company.